Literature DB >> 1568209

Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound, 1,4-phenylenebis(methylene)selenocyanate.

K el-Bayoumy1, Y H Chae, P Upadhyaya, C Meschter, L A Cohen, B S Reddy.   

Abstract

We synthesized a novel organoselenium compound, 1,4-phenylenebis(methylene)selenocyanate (XSC), possessing low toxicity by comparison with inorganic Na2SeO3, and several other synthetic organoselenium compounds (K. El-Bayoumy, Cancer Res., 45: 3631-3636, 1985). We tested the effect of XSC treatment during the initiation phase on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma formation. A semipurified high-fat diet containing 80 ppm of XSC (40 ppm as selenium) was fed to 6-wk-old virgin female Sprague-Dawley rats for 2 wk, starting 1 wk before and ending 1 wk after carcinogen treatment. At 7 wk of age, rats were given a single dose of DMBA (5 mg) in 0.2 ml of olive oil by gastric intubation; the experiment was terminated 16 wk later. The development of mammary tumors in those rats that received XSC-supplemented diets was significantly inhibited when compared with the control group (fed the same diet without XSC supplements). This was evident from tumor incidence (percentage of tumor-bearing rats, 88 versus 20) and multiplicity of tumors (mean number of tumors/rats, 3.96 versus 0.28). The finding that XSC acts as a chemopreventive agent in the DMBA mammary tumor model prompted us to examine the effect of dietary XSC on DMBA-DNA binding in both the liver and mammary tissue under conditions identical to those described above for the bioassay. Rats (four/group) were killed 6, 24, 48, and 168 h after [3H]DMBA (5 mg/rat; specific activity, 51.2 mCi/mM) administration. Liver and mammary tissue were obtained and DNA was isolated. Dietary XSC was found to inhibit total DMBA-DNA binding in the mammary tissue, but not in the liver. The most profound effect was observed at early time points, i.e., 24 to 48 h after [3H]DMBA administration. The inhibition in total binding was attributed to a reduction in the formation of the three major adducts derived from bay-region diol-epoxides of DMBA; these were identified as anti-diol-epoxide:deoxyguanosine, syn-diol-epoxide:deoxyadenosine, and anti-diol-epoxide:deoxyadenosine adducts on the basis of their chromatographic characteristics on high-pressure liquid chromatography and on a boronate affinity column. The inhibition of the DMBA-DNA binding in the target tissue provides a plausible explanation for the chemopreventive effect of XSC during the initiation stage of carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568209

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.

Authors:  Nicole D Facompre; Indu Sinha; Karam El-Bayoumy; John T Pinto; Raghu Sinha
Journal:  Int J Cancer       Date:  2012-03-20       Impact factor: 7.396

2.  XPD Lys751Gln increases the risk of breast cancer.

Authors:  Mani Samson; Shirley Sunder Singh; Ranganathan Rama; Veluswami Sridevi; Thangarajan Rajkumar
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

3.  Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds.

Authors:  Tsutomu Shimada; Norie Murayama; Katsuhiro Tanaka; Shigeo Takenaka; F Peter Guengerich; Hiroshi Yamazaki; Masayuki Komori
Journal:  Chem Res Toxicol       Date:  2011-07-20       Impact factor: 3.739

4.  Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway.

Authors:  Gowdahalli Krishnegowda; A S Prakasha Gowda; Hephzibah Rani S Tagaram; Kevin F Staveley-O' Carroll; Rosalyn B Irby; Arun K Sharma; Shantu Amin
Journal:  Bioorg Med Chem       Date:  2011-08-26       Impact factor: 3.641

Review 5.  Chemopreventive mechanisms of selenium.

Authors:  G F Combs
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 6.  Mammary tumorigenesis and chemoprevention studies in carcinogen-treated rats.

Authors:  C Ip
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-01       Impact factor: 2.673

7.  A facile synthesis of substituted benzyl selenocyanates.

Authors:  Linda A Jacob; Bianca Matos; Corey Mostafa; Joelle Rodriguez; Joanne Kivella Tillotson
Journal:  Molecules       Date:  2004-07-31       Impact factor: 4.411

8.  Effects of 1,4-phenylenebis(methylene)selenocyanate on mutagenesis and p53 protein expression in the tongue of lacI rats treated with 4-nitroquinoline-N-oxide.

Authors:  Joseph Guttenplan; Kun-Ming Chen; Michael Khmelnitsky; Wieslawa Kosinska; Jeannie Hennessy; Richard Bruggeman; Dhimant Desai; Shantu Amin; Yuan-Wan Sun; Tomas E Spratt; Karam El-Bayoumy
Journal:  Mutat Res       Date:  2007-07-17       Impact factor: 2.433

9.  Influence of novel naphthalimide-based organoselenium on genotoxicity induced by an alkylating agent: the role of reactive oxygen species and selenoenzymes.

Authors:  Somnath Singha Roy; Pramita Chakraborty; Prosenjit Ghosh; Sulekha Ghosh; Jaydip Biswas; Sudin Bhattacharya
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

10.  Modulations of benzo[a]pyrene-induced DNA adduct, cyclin D1 and PCNA in oral tissue by 1,4-phenylenebis(methylene)selenocyanate.

Authors:  Kun-Ming Chen; Peter G Sacks; Thomas E Spratt; Jyh-Ming Lin; Telih Boyiri; Joel Schwartz; John P Richie; Ana Calcagnotto; Arunangshu Das; James Bortner; Zonglin Zhao; Shantu Amin; Joseph Guttenplan; Karam El-Bayoumy
Journal:  Biochem Biophys Res Commun       Date:  2009-04-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.